AVZOClinical Trials•businesswire•
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
Sentiment:Positive (70)
Summary
(AVZO) SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces FDA Clearance of IND Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific ADC
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by businesswire